Massive Bio, FOMAT launch AI cancer trial prescreening pilot

Massive Bio has partnered with FOMAT to add AI-powered prescreening for oncology clinical trials across FOMAT’s community-based research network. The June 2026 pilot aims to speed trial matching and expand access for cancer patients before a broader rollout is considered.

Why it matters: - Cancer patients often miss clinical trial opportunities because eligibility matching is fragmented, delayed or never happens. - Earlier prescreening can shorten the path from diagnosis to a potential trial and reduce the burden on patients and research sites. - The pilot focuses on community-based settings, where access barriers and underrepresentation in research remain persistent issues.

What happened: - Massive Bio announced a partnership with FOMAT in June 2026 to support AI-powered patient prescreening for oncology clinical trials. - The collaboration is running a pilot project across FOMAT’s community-based research network before any broader expansion. - FOMAT is headquartered in Oxnard, California. - FOMAT became the largest Embedded Research Organization in the United States after acquiring Topography Health’s research site business unit in May 2026.

The details: - Massive Bio’s AI platform will analyze patient profiles inside FOMAT’s physician network to identify possible oncology trial eligibility. - Patients flagged through prescreening will be guided toward matched trials. - The integrated workflow is designed to test both efficiency and scalability. - FOMAT now operates more than 40 investigator sites across six states: Maryland, California, Colorado, New Mexico, Michigan and North Carolina. - FOMAT embeds clinical research into standard-of-care settings. - FOMAT says 91% of its recruitment comes through its community partner network. - Massive Bio serves patients across 17 markets and has facilitated more than 19,000 clinical trial matches. - Massive Bio’s AI platform is backed by a peer-reviewed prospective study in ESMO Real World Data and Digital Oncology showing four times faster trial matching across 3,804 real-world cancer patients. - Massive Bio has received the DiMe Seal from the Digital Medicine Society and is listed in the CMS Medicare App Library, connecting its platform to more than 68 million Medicare beneficiaries. - More information is available on Massive Bio’s website. - More information is available on FOMAT’s website.

Between the lines: - The partnership combines two complementary models: Massive Bio’s AI matching and FOMAT’s embedded site network. - The setup could help move trial identification closer to routine care, which may matter most for patients who are underrepresented in oncology research. - Starting with a pilot gives both companies room to measure performance before scaling a broader rollout.

What’s next: - Massive Bio and FOMAT are evaluating outcomes and patient reach during the pilot phase. - The companies will decide the timeline and scope of a wider expansion after reviewing the pilot results. - If the workflow performs well, the collaboration could extend across FOMAT’s full network and reach more oncology patients in community settings.

The bottom line: - The partnership aims to make cancer trial matching faster, more precise and more accessible by putting AI prescreening inside routine care settings.